The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy

Clinical Colorectal Cancer

Volumn 15, Issue 4, 2016, Pages 285-291

  Toh, James W T ^a,b,c,d,e,f   de Souza, Paul ^a,b,c,e,g   Lim, Stephanie H ^a,c,e   Singh, Puneet ^a,e   Chua, Wei ^e,g   Ng, Weng ^e,g   Spring, Kevin J ^a,b,c,e  

^a INGHAM INSTITUTE FOR APPLIED MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Centre for Oncology Education and Research Translation (CONCERT)   (Australia)

^f WESTMEAD HOSPITAL   (Australia)

^g LIVERPOOL HOSPITAL   (Australia)

Author keywords

Microsatellite instability; Nivolumab; PD L1; Pembrolizumab; TILs

Indexed keywords

GAMMA INTERFERON; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; COLORECTAL CANCER; DISEASE COURSE; DRUG RESPONSE; HUMAN; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; MICROSATELLITE INSTABILITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; GENETICS; IMMUNOTHERAPY; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; MICROSATELLITE INSTABILITY; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84996445447     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2016.07.007     Document Type: Review

References (56)

1. 1 Thibodeau, S.N., Bren, G., Schaid, D., Microsatellite instability in cancer of the proximal colon. Science 260 (1993), 816–819.
2. 2 Soreide, K., Janssen, E.A., Soiland, H., Korner, H., Baak, J.P., Microsatellite instability in colorectal cancer. Br J Surg 93 (2006), 395–406.
3. 3 Boland, C.R., Thibodeau, S.N., Hamilton, S.R., et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (1998), 5248–5257.
4. 4 Le, D.T., Uram, J.N., Wang, H., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
5. 5 Gatalica, Z., Snyder, C.L., Yeatts, K., Xiao, N., Holterman, D., Lynch, H.T., Programmed death 1 (PD-1) lymphocytes and ligand (PD-L1) in colorectal cancer and their relationship to microsatellite instability status. J Clin Oncol, 32, 2014, 5s (suppl; abstr 3625).
6. 6 Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
7. 7 Llosa, N.J., Housseau, F., Wick, E.C., et al. Immune checkpoints expression in MSI versus MSS colorectal cancers and their potential therapeutic implications. J Clin Oncol, 32, 2014, 5s (suppl; abstr 3620).
8. 8 Llosa, N.J., Cruise, M., Tam, A., et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5 (2015), 43–51.
9. 9 Naito, Y., Saito, K., Shiiba, K., et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58 (1998), 3491–3494.
10. 10 Deschoolmeester, V., Baay, M., Van Marck, E., et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol, 11, 2010, 19.
11. 11 Deschoolmeester, V., Baay, M., Lardon, F., Pauwels, P., Peeters, M., Immune cells in colorectal cancer: prognostic relevance and role of MSI. Cancer Microenviron 4 (2011), 377–392.
12. 12 Michael-Robinson, J.M., Biemer-Huttmann, A., Purdie, D.M., et al. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 48 (2001), 360–366.
13. 13 Ling, K.L., Pratap, S.E., Bates, G.J., et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun, 7, 2007, 7.
14. 14 Ling, A., Edin, S., Wikberg, M.L., Oberg, A., Palmqvist, R., The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. Br J Cancer 110 (2014), 2551–2559.
15. 15 Svennevig, J.L., Lunde, O.C., Holter, J., Bjorgsvik, D., Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer 49 (1984), 375–377.
16. 16 Jass, J.R., Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 39 (1986), 585–589.
17. 17 Shunyakov, L., Ryan, C.K., Sahasrabudhe, D.M., Khorana, A.A., The influence of host response on colorectal cancer prognosis. Clin Colorectal Cancer 4 (2004), 38–45.
18. 18 Dahlin, A.M., Henriksson, M.L., Van Guelpen, B., et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 24 (2011), 671–682.
19. 19 Chiba, T., Ohtani, H., Mizoi, T., et al. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer 91 (2004), 1711–1717.
20. 20 Zlobec, I., Lugli, A., Baker, K., et al. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. J Pathol 212 (2007), 260–268.
21. 21 Prall, F., Duhrkop, T., Weirich, V., et al. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 35 (2004), 808–816.
22. 22 Ogino, S., Nosho, K., Irahara, N., et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 15 (2009), 6412–6420.
23. 23 Pages, F., Berger, A., Camus, M., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353 (2005), 2654–2666.
24. 24 Mlecnik, B., Tosolini, M., Kirilovsky, A., et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29 (2011), 610–618.
25. 25 Sargent, D.J., Marsoni, S., Monges, G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28 (2010), 3219–3226.
26. 26 Sinicrope, F.A., Foster, N.R., Thibodeau, S.N., et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103 (2011), 863–875.
27. 27 Webber, E.M., Kauffman, T.L., O'Connor, E., Goddard, K.A., Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5–FU-based chemotherapy. BMC Cancer, 15, 2015, 156.
28. 28 Xiao, Y., Freeman, G.J., The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov 5 (2015), 16–18.
29. 29 Overman, M.J., Kopetz, S., McDermott, R.S., Leach, J., et al. A study of nivolumab and nivolumab plus ipilimumab in recurrent and metastatic colon cancer (CheckMate 142). J Clin Oncol, 34, 2016 suppl; abstr 3501.
30. 30 Chen, L., Han, X., Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125 (2015), 3384–3391.
31. 31 Zinselmeyer, B.H., Heydari, S., Sacristan, C., et al. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med 210 (2013), 757–774.
32. 32 de Guillebon, E., Roussille, P., Frouin, E., Tougeron, D., Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol 7 (2015), 95–101.
33. 33 Fulchiero, E., Jimeno, A., Nivolumab. Drugs Today (Barc) 50 (2014), 791–802.
34. 34 Luke, J.J., Ott, P.A., PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget 6 (2015), 3479–3492.
35. 35 Kroemer, G., Galluzzi, L., Zitvogel, L., Fridman, W.H., Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. Oncoimmunology, 4, 2015, e1058597.
36. 36 Wu, X., Zhang, H., Xing, Q., et al. PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Br J Cancer 111 (2014), 1391–1399.
37. 37 Droeser, R.A., Hirt, C., Viehl, C.T., et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 49 (2013), 2233–2242.
38. 38 Popat, S., Hubner, R., Houlston, R.S., Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23 (2005), 609–618.
39. 39 Muller, C.I., Schulmann, K., Reinacher-Schick, A., et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis 23 (2008), 1033–1039.
40. 40 Kazama, S., Watanabe, T., Ajioka, Y., Kanazawa, T., Nagawa, H., Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2. Br J Cancer 94 (2006), 293–298.
41. 41 Buckowitz, A., Knaebel, H.P., Benner, A., et al. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer 92 (2005), 1746–1753.
42. 42 Lochhead, P., Kuchiba, A., Imamura, Y., et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 105 (2013), 1151–1156.
43. 43 Taube, J.M., Klein, A., Brahmer, J.R., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20 (2014), 5064–5074.
44. 44 Fusi, A., Festino, L., Botti, G., et al. PD-L1 expression as a potential predictive biomarker. Lancet Oncol 16 (2015), 1285–1287.
45. 45 Maby, P., Tougeron, D., Hamieh, M., et al. Correlation between density of CD8+ T cell infiltrates in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res 75 (2015), 3446–3455.
46. 46 Lynch, P.M., The case for universal testing of colorectal tumors for microsatellite instability: a coming mismatch between clinical and laboratory testing. Dig Dis Sci 60 (2015), 2225–2227.
47. 47 Dolcetti, R., Viel, A., Doglioni, C., et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 154 (1999), 1805–1813.
48. 48 Lal, N., Beggs, A.D., Willcox, B.E., Middleton, G.W., An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy. Oncoimmunology, 4, 2015, e976052.
49. 49 Huh, J.W., Kim, H.C., Kim, S.H., et al. Mismatch repair system and p53 expression in patients with T1 and T2 colorectal cancer: predictive role of lymph node metastasis and survival. J Surg Oncol 109 (2014), 848–852.
50. 50 Emterling, A., Wallin, A., Arbman, G., Sun, X.F., Clinicopathological significance of microsatellite instability and mutated RIZ in colorectal cancer. Ann Oncol 15 (2004), 242–246.
51. 51 Sun, Z., Yu, X., Wang, H., Zhang, S., Zhao, Z., Xu, R., Clinical significance of mismatch repair gene expression in sporadic colorectal cancer. Exp Ther Med 8 (2014), 1416–1422.
52. 52 Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr., Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
53. 53 de la Chapelle, A., Hampel, H., Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 28 (2010), 3380–3387.
54. 54 Piton, N., Borrini, F., Bolognese, A., Lamy, A., Sabourin, J.C., KRAS and BRAF mutation detection: is immunohistochemistry a possible alternative to molecular biology in colorectal cancer?. Gastroenterol Res Pract, 2015, 2015, 753903.
55. 55 Sorbye, H., Dragomir, A., Sundstrom, M., et al. High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. PLoS One, 10, 2015, e0131046.
56. 56 Seppala, T.T., Bohm, J.P., Friman, M., et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer 112 (2015), 1966–1975.